

NEWS ANNOUNCEMENT - FOR IMMEDIATE RELEASE

October 17th, 2023

Milan, Italy

Mark Lovern Joins InSilicoTrials as Chief Platform Officer

17th October 2023 – Today, InSilicoTrials warmly welcomes **Dr. Mark Lovern** in his new role as **Chief Platform Officer**, a move marking the company's continued commitment to leading the frontier of AI-driven innovation and simulation in life sciences.

With the digital transformation revolution reshaping various industries, the role of Chief Platform Officer becomes even more pivotal.

Dr. Lovern will combine his scientific knowledge with cutting-edge **Artificial Intelligence (AI), Machine Learning (ML)** and **simulation** technologies, along with an in-depth understanding of **regulatory** science, to drive the development of the [InSilicoTrials.com platform](https://www.insilicotrials.com) and position it as a catalyst for hyper-accelerating life science R&D.



“Mark’s extensive experience and mastery in model-informed drug development align seamlessly with our vision of revolutionizing the life sciences industry,” commented Luca Emili, CEO at InSilicoTrials. *“His prior achievements, combined with our groundbreaking AI and simulations platform, will surely take our capabilities to unprecedented heights.”*, he added.

In his strategic role, Dr. Mark Lovern will employ data integration and AI to enhance predictive accuracy for compound safety and efficacy.

Drawing from his extensive background and expertise in **modeling tools**, Dr. Lovern aims to cultivate a culture of innovation within InSilicoTrials, revolutionizing its operational efficiency and client service.

Dr. Mark Lovern brings in a rich history, having 25+ years of experience in the application of **model-informed drug development (MIDD)**.

InSilicoTrials

Riva Grumula 2,
34123 Trieste, Italy

info@insilicotrials.com
www.insilicotrials.com

In addition to **modeling** pharmacokinetic and pharmacodynamic data across a wide variety of compounds and therapeutic areas, Mark has also taught over 50 technical training workshops on modeling tools and methodology. His most recent therapeutic area experience has been with therapies for infectious disease, metabolic, and autoimmune disorders. Before joining InSilicoTrials as Chief Platform Officer, he had gathered extensive experience in both consultancy (Certara) and biopharma companies (GSK and UCB), contributing significantly to the field of quantitative pharmacology.

[InSilicoTrials](#)

InSilicoTrials specializes in leveraging AI and simulations to enhance drug and medical device development. Using in silico techniques, it analyzes data to predict safety and efficacy of potential compounds, aiding Pharma, MedTech companies, and researchers in efficient, cost-effective advancement by minimizing extensive clinical trials. Its cloud-based platform offers advanced tools for in silico trials analyses, facilitating the integration of AI and simulation technology into development workflows.

InSilicoTrials

Riva Grumula 2,
34123 Trieste, Italy

info@insilicotrials.com
www.insilicotrials.com